Notably, liver deletion of SCAP also prevents fatty liver in diabetic, high-carbohydrate diet, and high-fat diet rodent models of NAFLD, demonstrating that the SREBP pathway is a therapeutic target for the treatment of NAFLD (7). This evidence concerns the gene SCAP and fatty liver disease.